NCT02261922

Ticagrelor and Endothelial Function

A Prospective Randomized Double Blind Study to Evaluate the Effect of Ticagrelor on Endothelial Function

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Hotel Dieu de France Hospital · Academic / Other
• Sex: All
• Age: 21 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the effect of ticagrelor on endothelial function as measured by flow mediated dilation of the brachial artery. This will be compared to prasugrel.

Detailed description

Objective: Demonstrate an improvement in endothelial function with ticagrelor Introduction and hypothesis: Ticagrelor and prasugrel are 2 new platelet antagonists. Both are superior to clopidogrel when used in acute coronary syndromes. However, only ticagrelor reduced cardiovascular mortality by almost 20%. Prasugrel reduced the composite clinical end point of cardiovascular mortality, myocardial infarction and stroke, but did not decrease mortality. The exact mechanism of mortality reduction with ticagrelor is unclear. Some side effects of ticagrelor, such as brady-arrhythmias and dyspnea may be related to adenosine release. It is thus possible, that this drug may liberate significant amount of adenosine. Prior studies have demonstrated that adenosine has beneficial effects on the endothelial function and that it improves the outcome of patient with acute coronary syndromes. It is thus possible that ticagrelor may improve endothelial function through an adenosine like effect. This effect is independent from platelet inhibition. Prasugrel has the same platelet inhibition effect compared to ticagrelor, but our hypothesis is that it does not have an adenosine like effect and thus does not improve endothelial function. Study design: This is a prospective, randomized, double blind, cross-over study comparing 2 new platelet inhibitors that have the same potency: ticagrelor and prasugrel. Patients with stable coronary artery disease will be randomized to one of these 2 drugs. Patients will receive one of the 2 drugs for a period of 8 +/- 2 days, they will then stop the drug for a period of 14 +/- 2 days, and they will then cross over and receive the other drug for a period of 8 +/- 2 days. All patients will have the following measurements: * Flow mediated Dilation (FMD) of the brachial artery * Platelet aggregation in response to ADP All measurements will be done at: * Baseline 1 (prior to starting drug 1) * At 8 +/- 2 days (peak effect of drug 1) * Baseline 2 (at 14+/- 2 days; after washout and prior to starting drug 2) * At 8 +/- 2 days after baseline 2 (peak effect of drug 2) Measure of FMD of the brachial artery: It will be performed according to the Academic Medical Center of Amsterdam pre-established protocol. Measure of platelet aggregation: It will be performed with the multiplate aggregometer Study End-Points: * Primary: change in FMD before and after each of the 2 drugs * Secondary: Change in platelet aggregation before and after each of the 2 drugs * Possible another secondary end-point: Change in NO activity in the blood before and after each of the 2 drugs

Conditions

• Antiplatelet Agents; Endothelial Function; Pleotropic Effects

Interventions

Type	Name	Description
DRUG	ticagrelor
DRUG	prasugrel

Timeline

• Start date: 2014-10-01
• Primary completion: 2015-10-01
• Completion: 2015-11-01
• First posted: 2014-10-10
• Last updated: 2014-10-10

Locations

1 site across 1 country: Lebanon